OPT logo

OPT Opthea Limited

NASDAQ Global Select · Biotechnology · Healthcare

$3.41
+0.05 (+1.49%)

Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D, along with VEGF Receptor-3. This proprietary founda…

Market Cap: $4.24Bceryvyn.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$3.41 – $3.41
52-Week Range
$1.79 – $6.30
Volume
$3.0K
Market Cap
$4.24B
50-Day Avg
$4.37
200-Day Avg
$3.53
Prev Close
$3.36
Open
$3.41

Valuation & Ratios

P/E Ratio
-3.28
EPS
$-1.07
P/B Ratio
-2.59
P/S Ratio
20881.09
Debt/Equity
-1.23
Current Ratio
0.22
Dividend Yield
+0.0%
Gross Margin
+100.0%

Returns & Efficiency

Return on Equity
+81.2%
Return on Assets
-286.9%
FCF Yield
-30.5%
EV/EBITDA
-5.83

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$25.0K$-163.79M$-1.04
2024$124.7K$-220.24M$-2.80
2023$108.0K$-211.88M$-3.60
2022$125.0K$-127.99M$-2.72
2021$92.0K$-60.79M$-1.44

Social Signal Score

50
5d
51
1 mentions
30d
50
1 mentions
60d
50
1 mentions
90d
50
1 mentions
news: 1

Earnings

1of 4 quarters beat consensus

Typical surprise -205.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 28$-0.20 vs $-0.05miss
  • Wed, Feb 26$-1.65 vs $-0.43miss
  • Wed, Oct 30$-1.23 vs $-0.54miss
  • Tue, Sep 12$-0.64 vs $-1.28beat

Estimates and results for OPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by OPT officers and directors.

No open-market trades in the recent filings. All 27 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.

27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

OPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsproactiveinvestors.co.uk·5h ago·Neutral

    Optima Health targets further growth after transformational year Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N), the provider of workplace health and wellbeing services, said it had entered its new financial year with strong momentum and remained confident of further growth. The company pointed to structural demand for occupational health, citing sustained pressure on NHS capacity and the government's Keep Britain Working agenda as drivers reinforcing the case for employer-led health provision.

    View source ↗